Cargando…
A two-faced selectivity solution to target SMARCA2 for cancer therapy
Two new studies exploring PROTAC-mediated degradation of SMARCA2 for cancer therapy solve an apparently intractable selectivity challenge with SMARCA4 by utilising the requirement for a productive ternary complex between the protein, PROTAC and ligase complex.
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889305/ https://www.ncbi.nlm.nih.gov/pubmed/36720862 http://dx.doi.org/10.1038/s41467-023-36238-0 |